ReviewBMC biotechnology2013
Microfluidic chip-based technologies: emerging platforms for cancer diagnosis.
Review in BMC biotechnology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Application of microfluidic technology based on surface-enhanced Raman scattering in cancer biomarker detection: A review.Journal of pharmaceutical analysis · 2023Review
- Towards a New 3Rs Era in the construction of 3D cell culture models simulating tumor microenvironment.Frontiers in oncology · 2023Review
- Advances in Microfluidics for the Implementation of Liquid Biopsy in Clinical Routine.Advances in experimental medicine and biology · 2022Article
- Microfluidic Platforms to Unravel Mysteries of Alzheimer's Disease: How Far Have We Come?Life (Basel, Switzerland) · 2021Review
- Scalable Signature-Based Molecular Diagnostics Through On-chip Biomarker Profiling Coupled with Machine Learning.Annals of biomedical engineering · 2020Review
- Biomedical applications of nanoflares: Targeted intracellular fluorescence probes.Nanomedicine : nanotechnology, biology, and medicine · 2019Review
- Microfluidic approaches for cell-based molecular diagnosis.Biomicrofluidics · 2018Article
- Biomimetics of the pulmonary environmentBiomicrofluidics · 2018Article
- Evaluation of disposable microfluidic chip design for automated and fast Immunoassays.Biomicrofluidics · 2017Article
- Microfluidics as a new tool in radiation biology.Cancer letters · 2016Review
- Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence.Chemical reviews · 2015Review
- Single-cell, locus-specific bisulfite sequencing (SLBS) for direct detection of epimutations in DNA methylation patterns.Nucleic acids research · 2015Article
- AGR3 in breast cancer: prognostic impact and suitable serum-based biomarker for early cancer detection.PloS one · 2015Article
- Article
- Benchtop technologies for circulating tumor cells separation based on biophysical properties.BioMed research international · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of early and personalized diagnostic protocols is considered the most promising avenue to decrease mortality from cancer and improve outcome. The emerging microfluidic-based analyzing platforms hold high promises to fulfill high-throughput and high-precision screening with reduced equipment cost and low analysis time, as compared to traditional bulky counterparts in bench-top laboratories. This article overviewed the potential applications of microfluidic technologies for detection and monitoring of cancer through nucleic acid and protein biomarker analysis. The implications of the technologies in cancer cytology that can provide functional personalized diagnosis were highlighted. Finally, the future niches for using microfluidic-based systems in tumor screening were briefly discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.